Abstract:AIM:To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC).METHODS:Thirty-two patients with extrahepatic metastasis of HCC after local treatment were prospectively enrolled. The CapeOx regimen consisted of capecitabine 1000 mg/m(2) taken orally twice daily on days 1-14, and oxaliplatin was administered at a total dose of 100 mg/m(2) on day 1. The treatment was repeated every 3 wk until disease progression or unaccetablle toxicity. Efficacy and safety were assessable for all enrolled patients. The primary objective of this study was to assess the overall response rate. The secondary objectives were to evaluate the overall survival (OS), the time to tumor progression (TTP) and the toxicity profile of the combined strategy. TTP and OS were assessed by the Kaplan-Meier method and differences between the curves were analyzed using the log-rank test. The statistical software SPSS version 15.0 for Windows (SPSS Inc., Chicago, IL, United States) was used for statistical analysis. All P values were 2-tailed, with statistical significance defined by P ≤ 0.05.RESULTS:Thirty-two patients were assessable for efficacy and toxicity. The median follow-up duration was 15 mo (range, 12-20 mo). At the cut-off date of March 31, 2012, 27 patients died due to tumor progression and one patient died of myocardial infarction. Four patients were still alive (three patients with disease progression). OR was 21.9% (n = 7), the stabilization rate was 40.6% (n = 13), and the disease control rate was 62.5%. The responses lasted from 4 to 19 mo (median, 6 mo). Median TTP was 4.2 mo (95%CI: 2.5-7.4), and the median OS time was 9.2 mo (95%CI: 6.5-17.8). The 1-year survival rate was 43.6% (95%CI: 29.0-66.0). In a multivariate analysis, OS was significantly longer in patients with a Child-Pugh class A compared with class B patients (P = 0.014), with a median OS of 10.1 mo vs 5.4 mo, and there were trends towards longer OS (P = 0.065) in patients without portal vein tumor thrombosis. There were no significant effects of age, gender, performance status, cirrhosis, metastatic sites, and level of alpha fetoprotein (AFP) or hepatitis B virus-DNA on OS. Among the 22 patients with elevated AFP levels at baseline (≥ 400 ng/mL), the level fell by more than 50% during treatment in 6 patients (27.3%). The most frequent treatment-related grade 3 to 4 toxicities included leucopenia/neutropenia, transient elevation of aminotransferases, hand-foot syndrome and fatigue.CONCLUSION:CapeOx showed modest anti-tumor activity in metastatic HCC. However, the manageable toxicity profile and the encouraging disease control rate deserve further study for these patients.

A Clinical Study on Inhibition of Lung Metastasis of Hepatocellular Carcinoma by Capecitabine

Study on Inhibition of the Growth and Metastasis of LCID20 Hepatocellular Carcinoma by Capecitabine

Capecitabine in Inhibition of Recurrence and Metastasis after Liver Cancer Resection in Nude Mice

Capecitabine Inhibits Postoperative Recurrence and Metastasis after Liver Cancer Resection in Nude Mice with Relation to the Expression of Platelet-Derived Endothelial Cell Growth Factor

Meta-Analysis Of Capecitabine-Based Chemotherapy Versus Capecitabine-Free Chemotherapy In Patients With Metastatic Breast Cancer

Therapeutic Effects and Toxic Side Reactions of Capecitabine Combined with A Modified Prescription of Fuzheng Jiedusan (resistance Strengthening and Detoxification Granules) on Advanced Gastric Cancer

Effects and safety of capecitabine maintenance therapy after combination chemotherapy for patients with breast cancer liver metastasis

Efficacy of Capecitabine and Oxaliplatin Regimen for Extrahepatic Metastasis of Hepatocellular Carcinoma Following Local Treatments.

Interferon-α and capecitabine inhibited the recurrence and metastasis of hepatocellular carcinoma after curative resection in nude mice

Clinical research on oxaliplatin or irinotecan plus capecitabine for colorectal liver metastasis treatment

The effect of Gemcitabine combined Capecitabine regimens for anthracycline-and taxane-refractory metastatic breast cancer

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer

Peginterferon-α combined with capecitabine inhibits tumor growth in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential

Study of the radiotherapy sensitization effects and mechanism of capecitabine (Xeloda) against non-small-cell lung cancer cell line A549.

Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.

Role of Capecitabine in Treating Metastatic Colorectal Cancer in Chinese Patients

Factors influencing bone metastasis in HER-2 negative breast cancer and the efficacy of capecitabine plus docetaxel

Tu1894 Ultrahigh-Throughput Screening Strategies for Identification of Small-Molecule Compounds That Target the Colon Cancer Oncogene KrüPpel-Like Factor 5

A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma

Capecitabine Plus Paclitaxel Induction Treatment in Gastric Cancer Patients with Liver Metastasis: a Prospective, Uncontrolled, Open-Label Phase II Clinical Study.